Krispy Kreme Doughnuts, Inc. Message Board

I am maxed out on qcor stock. I have been looking at the qcor LEAPS, Jan 14 @50 to $52.50 to $55 range. Any expert opinions about where the best value is within these particular LEAPS?
TIA

Sentiment: Strong Buy

is remains utterly insane for qcor to be selling at these levels. Run the earnings yield -use last 4 Q's so not factoring in any future growth- and is it amazing. No debt, paying a very nice dividend and selling at 10X trailing earnings? qcor should now be selling for at LEAST 15x earnings.
Someday in the not too distant future QCOR will break the back of the short's stranglehold and then it is Katy bar the door. If not, QCOR simply contnues buying back their own shares and that alone will do the trick.
In for the LONG HAUL...

Sentiment: Strong Buy

I'm thinking of wading in and buying some of the Jan 14 call options. I'd appreciate some knowledgeable opinions of what you think may be the best priced ones. Looks to me there are several still attractively priced?

THanks in advance!

Sentiment: Strong Buy

nalyst? Research Firm? Signal? Signal Date? Initial Price? Price Target? Closing Date? Return?
Juan Sanchez Ladenburg Thalmann & Co. Buy Feb 26, '13 32.37 38.00 Feb 26, '14 18.60%
Biren Amin Jefferies & Co. Buy Feb 26, '13 32.37 38.00 Feb 26, '14 18.60%
Joshua Schimmer Lazard Capital Markets Buy Dec 30, '12 26.48 74.00 Dec 30, '13 44.98%
Joshua Schimmer Lazard Capital Markets Buy Nov 14, '12 24.89 74.00 Nov 14, '13 54.24%
Juan Sanchez Ladenburg Thalmann & Co. Buy Oct 23, '12 25.32 33.00 Oct 23, '13 51.62%
Juan Sanchez Ladenburg Thalmann & Co. Buy Sep 19, '12 25.73 45.00 Sep 19, '13 49.20%
Steve Byrne BofA Merrill Lynch Buy Sep 19, '12 25.73 45.00 Sep 19, '13 49.20%
David Amsellem Piper Jaffray Buy Sep 19, '12 25.73 67.00 Sep 19, '13 49.20%
Tim Chiang CRT Capital Group Buy Sep 19, '12 25.73 57.00 Sep 19, '13 49.20%
Joshua Schimmer Lazard Capital Markets Buy Sep 19, '12 25.73 74.00 Sep 19, '13 49.20%
Christopher Holterhoff Oppenheimer & Co. Buy Sep 17, '12 48.93 69.00 Sep 17, '13 -21.54%
Biren Amin Jefferies & Co. Buy Sep 06, '12 49.11 60.00 Sep 06, '13 -21.83%
Joshua Schimmer Lazard Capital Markets Buy Sep 04, '12 46.67 67.00 Sep 04, '13 -17.74%
Tim Chiang CRT Capital Group Buy Aug 08, '12 37.75 62.00 Aug 08, '13 1.70%
Joshua Schimmer Lazard Capital Markets Buy Aug 06, '12 37.02 51.00 Aug 06, '13 34.53%
Steve Byrne BofA Merrill Lynch Buy Jul 12, '12 44.41 60.00 Jul 12, '13 -13.56%
Christopher Holterhoff Oppenheimer & Co. Buy Jun 14, '12 45.32 59.00 Jun 14, '13 -15.29%
Biren Amin Jefferies & Co. Buy Jun 14, '12 45.32 56.00 Jun 14, '13 20.66%
Juan Sanchez Ladenburg Thalmann & Co. Buy Jun 10, '12 44.21 55.00 Jun 10, '13 21.49%
Biren Amin Jefferies & Co. Buy Apr 24, '12 40.68 52.00 Apr 24, '13 24.82%

Sentiment: Strong Buy

just wait until qcor steps in with their pre-authorized stock buy-backs. The impact of potential LARGE purchases should not be understated (especially with such large short positions).

Sentiment: Strong Buy

oh, the pain of it all....well, we tried to educate them

Sentiment: Strong Buy

1-800-go pound

Sentiment: Strong Buy

as a great general once said...never take counsel of your fears. Time for reflection on the MINIMAL value of QCOR.
as some shorts have posited...present share price may be very dangerous(?) due to driving down the share price(again?) -
if that happens just BUY more. If it doesnt happen just enjoy the $$$. In the long run, as Keynes said, we are all dead. But in the short run we are all alive...bear raids/short sellers , when they are successful, merely provide another cheap buying opportunity.
So to the longer term investor, this is all noise anyway.
10x PE/extremely LOW PEG/tons of cash/paying a nice dividend which may be increasing/share buybacks/many "call" options at NO cost (ALS/migraines/'DN/ et al) and still selling ~ 50% BELOW 52 week high? At the present share price there is NO growth priced into QCOR shares...so shorts...
Shorts,...please attack....I am waiting in the wings to simply BUY more at these ridiculously LOW prices.
ps I am making 5% on my lowest cost lots now...sitting and waiting for the inevitable rise in share price feels pretty good

Sentiment: Strong Buy

serious upward push going on...(lets see if it lasts).
I suspect road show next week may have some positives, so this could be a very short term catalysts for the share price.

Sentiment: Strong Buy

Just heard DAVID EINHORN will cover once GMCR resumes trading
5 minutes ago by analinspection

0/1

3

28 seconds agoby tomf91

SEC RESUME TRADING,, don't wait for EINHORN to cover !! OPEN at $60 GAP NEEDS TO BE FI...
2 minutes 11 seconds ago by analinspection

0/0

1

1 minute 29 seconds agoby dustbuster61

DAVID EINHORN was seen digging his own grave !!!
3 minutes 4 seconds ago by fraudstreetnow

0/0

0

3 minutes 4 seconds agoby fraudstreetnow

What is GAAP EPS AND NONE GAAP EPS?
3 minutes 40 seconds ago by dmrj697

0/0

0

3 minutes 40 seconds agoby dmrj697

we will be back to $70 tomorrow, EINHORN eat my pooooop
4 minutes 15 seconds ago by wizardofpussy

Sentiment: Strong Buy

New Hope For People With Fatal Muscular Disease ALS?
BY SIVAN KRIBOSHE, NOCAMELS · JANUARY 25, 2012 · 10 COMMENTS
HEALTH NEWS · TAGGED: ALS, FEATURED, HEALTH NEWS, PICTURES, STEM CELLS, TREATMENT

The Israeli biotechnology company BrainStorm announced successful results in its clinical trial for a drug against ALS (Amyotrophic Lateral Sclerosis) – a fatal neurodegenerative disease also known as Lou Gehrig’s disease.

The stem cell therapy with the drug NurOwn did not show significant side effects and the treatment has so far proven to be safe, the company said. The U.S. Food and Drug Administration last year granted orphan drug designation to NurOwn.

Patients in the trial are transplanted with stem cells derived from their own bone marrow and treated with the NurOwn stem cell technology.

Related Stories:
Artifcial Blood Vessels Created To Cure Diseases
New ‘Seek And Destroy’ Method To Fight Cancer

The initial phase of the study is designed to establish the safety of NurOwn and will later be expanded to assess efficacy.

However, the patients in the trial have already shown positive results. Among the six first patients, four have shown signs of improvement and the other two have experienced stabilization, meaning their medical condition stopped deteriorating.

“Even though we are conducting a safety trial, the early clinical follow-up of the patients treated with the stem cells shows indications of beneficial clinical effects, such as an improvement in breathing and swallowing ability as well as in muscular power,” Dimitrios Karussis, head of Israel’s Hadassah Medical Center‘s Multiple Sclerosis unit, who is leading the clinical trial, said in a press release.

“Patients treated with the Company’s NurOwn therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm‘s therapy has the potential to cure underlying pathology, rather than simply treat symptoms,” the company says.

ALS tends to affect people over the age of